On the other hand, real-world studies and systematic reviews have reported a link between anti-VEGF therapy and several systemic side effects, including deterioration of systemic hypertension, renal dysfunction, gastrointestinal perforation, stroke, myocardial infarction, and thromboembolic events [65,66]. Here, VEGFA is linked to myocardial infarction.